TNF and irritable bowel syndrome: So far no increased risk for severe COVID-19 could be observed for patients treated with anti-IL-12/IL-23 antibodies in the IBD-SECURE registry when compared to patients receiving anti-TNF-antagonists, suggesting that Il-12/IL-23 blockers should be considered as safe immunemodulators58.